Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 million

Reuters2026/08/03 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Design Therapeutics posted a Q2 net loss of USD 20.2 million, widening from USD 19.1 million a year earlier.
RD expenses rose to USD 16.4 million from USD 15.7 million, while GA expenses edged down to USD 5.8 million from USD 5.83 million.
Cash, cash equivalents and investment securities slipped to USD 207.4 million at June 30 from USD 219.8 million at Dec. 31.
RESTORE-FA trial modifications keep 1 mpk as the planned go-forward dose, targeting 10 patients in the 12-week cohort; 12-week data are expected in Q1 2027.
Management said four-week RESTORE-FA data showed DT-216P2 increased endogenous frataxin; dosing began in a Phase 1 MAD trial of DT-818 in DM1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030800PRIMZONEFULLFEED9802237) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 million

You may also like

Crypto prices